The SA Health Regulatory Products Authority (SAHPRA) has given the US-listed company, Oramed Pharmaceuticals, permission to start enrolling patients in a phase 1 trial. A similar trial is planned in Israel and a phase 2 trial in the US, reported Bloomberg News (29 October 2021).

The dose produced by Oramed’s subsidiary, Oravax, uses avirus-like particleto target three of Covid-19’s surface proteins, including those less susceptible to mutation.

According to a spokesperson for Oramed the oral form (tablets) “would eliminate several barriers to rapid, wide-scale distribution, potentially enabling people to administer the vaccine themselves at home”. While the tablets may need to be refrigerated, the hope is that the trials will show that the vaccine is stable at room temperature. The tablets will be “way cheaper” than shots produced by Moderna and Pfizer. Tablets also generally have fewer side effects than injections.

Other news